Surge Therapeutics’ CEO & Founder Michael Goldberg
Surge Therapuetics
Surge Therapeutics Develops Innovative Treatment to Prevent Cancer Recurrence
When an individual undergoes surgery to remove a localized tumor, there is a risk of the tumor growing back due to immune system suppression caused by the surgery. Surge Therapeutics, based in Cambridge, aims to address this issue through its novel hydrogel immunotherapy treatment. Their product, applied after tumor removal, aims to reduce the chances of cancer recurrence.
In a recent announcement, Surge Therapeutics revealed that it has secured $32 million in a Series B funding round. This brings the total venture investments for the company to $60 million. The funds will be used to further develop their immunotherapy treatment and advance clinical trials.
The unique aspect of Surge’s solution is that it is administered during surgery, unlike other immunotherapies that are given before or after the procedure. Michael Goldberg, CEO and founder of the company, highlights the critical nature of the time surrounding surgery and the need for treatment during that period.
Goldberg’s background in biology and his experience under the mentorship of renowned figures in the field led him to establish Surge Therapeutics in 2018. The company’s mission is to prevent cancer recurrence following surgery and ultimately save lives.
Surge Therapeutics received its first IND from the FDA in 2023 and initiated its first clinical trial in the same year. The trial involved the application of their candidate, STM-416, in patients with recurrent bladder cancer. The treatment released a hydrogel containing an antitumor drug at the site of tumor removal, aiming to improve survival outcomes.
The Series B funding round, led by Bioluminescence Ventures and including participation from other firms, will support gathering clinical data and advancing the three programs through phase one and phase 2A. The objective is to generate proof of concept data that demonstrates the effectiveness of Surge’s product in preventing cancer recurrence.
Phil Grayeski, partner at KdT Ventures, believes that intraoperative immunotherapy will become the standard of care. He praises Surge Therapeutics for providing a simple and non-toxic solution that directly targets the tumor and reprograms the immune system.
Goldberg envisions a transformative impact on cancer treatment and expresses excitement about the potential of Surge’s solution to revolutionize patient care.
MORE AT FORBES
Denial of responsibility! TechCodex is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
Jessica Irvine is a tech enthusiast specializing in gadgets. From smart home devices to cutting-edge electronics, Jessica explores the world of consumer tech, offering readers comprehensive reviews, hands-on experiences, and expert insights into the coolest and most innovative gadgets on the market.
